Genistein Administration Mitigating Radiation-Induced Erectile Dysfunction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods inadequately mitigate erectile dysfunction as a side effect of radiation therapy for prostate cancer, with existing treatments showing limited effectiveness in reducing its severity and incidence.

Innovation Solution

Administration of a therapeutic dosage of genistein, starting at least three days before and continuing up to two weeks prior to, during, and after radiation therapy, to address oxidative stress and inflammation causing erectile dysfunction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If radiation therapy is administered to treat prostate cancer, then cancer treatment effectiveness is improved, but erectile dysfunction occurs as a harmful side effect

Engineering Contradiction:
Improvecancer treatment effectivenessVSAvoiderectile dysfunction
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Genistein is administered before radiation therapy begins (starting 3-5 days prior) to pre-condition the penile tissue and establish protective mechanisms against oxidative stress before the harmful radiation exposure occurs

Inventive Principle:
Principle #9Preliminary anti-action

Solution Approach 2:

Genistein acts as an intermediary substance that mediates between the harmful radiation therapy and the penile tissue, scavenging free radicals and reducing oxidative stress to prevent radiation-induced damage while allowing the cancer treatment to proceed

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If genistein administration period is extended before and after radiation therapy, then mitigation of erectile dysfunction is improved, but treatment complexity increases

Engineering Contradiction:
Improvemitigation of erectile dysfunctionVSAvoidtreatment regimen complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

Genistein administration begins 3-5 days before radiation therapy to pre-condition the tissue with protective mechanisms, and continues for 2-4 weeks after to ensure complete mitigation, establishing a defined temporal framework that simplifies treatment planning

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The treatment protocol uses periodic administration of genistein at specific intervals before and after radiation therapy, creating a structured regimen that balances effectiveness with manageable treatment complexity

Inventive Principle:
Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Genistein effectively reduces the adverse side effect of erectile dysfunction by scavenging reactive oxygen species, improving vascular function and blood flow, thereby mitigating radiation-induced damage.

Implementation Method 1

genistein's ability to mitigate the sexual adverse effect of erectile dysfunction associated with radiation therapy for prostate cancer is mediated via genistein's anti-inflammatory properties and its ability, when administered in therapeutically sufficient dosage, to scavenge the reactive oxygen species responsible for the cellular damage that results in erectile dysfunction

Methodology Applied
Scientific EffectScavenging reactive oxygen species: Oxidation

Data Source

PatentEP2832356B1Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer
Publication Date: 2020.01.15 HUMANETICS CORP

AI summary

A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to commencement of radiation therapy for prostate cancer and extends beyond conclusion of the radiation therapy.